Literature DB >> 12717860

Repression of allo-cell transplant rejection through CIITA ribonuclease P+ hepatocyte.

Rong Guo1, Ping Zou, Hua-Hua Fan, Feng Gao, Qing-Xin Shang, Yi-Lin Cao, Hua-Zhong Lu.   

Abstract

AIM: Allo-cell transplant rejection and autoimmune responses were associated with the presence of class II major histocompatibility complex (MHC II) molecules on cells. This paper studied the effect of Ribonuclease P (RNase P) against CIITA, which was a major regulator of MHCII molecules, on repressing the expression of MHCII molecules on hepatocyte.
METHODS: M1-RNA is the catalytic RNA subunit of RNase P from Escherichia coli. It were constructed that M1-RNA with guide sequences (GS) recognizing the 452, 3408 site of CIITA by PCR from pTK117 plasmid, then were cloned into the EcoRI/BglII or EcoR//SalIsite of vector psNAV (psNAV-M1-452-GS, psNAV-M1-3408-GS) respectively. The target mould plate (3176-3560) of CIITA was obtained from Raji cell by RT-PCR, and then inserted into the XhoI/EcoRIof pGEM-7zf(+) plasmid (pGEM-3176). These recombinant plasmids were screened out by sequence analysis. psNAV-M1-452-GS, psNAV-M1-3408-GS and its target RNA pGEM-3176 were transcribed and then mixed up and incubated in vitro. It showed that M1-3408-GS could exclusively cleave target RNA that formed a base pair with the GS. Stable transfectants of hepatocyte cell line with psNAV-M1-3408-GS were tested for expression of class II MHC through FCM, for mRNA abundance of MHCII, Ii and CIITA by RT-PCR., for the level of IL-2 mRNA on T cell by mixed lymphocyte reaction.
RESULTS: When induced with recombinant human interferon-gamma (IFN-gamma), the expression of HLA-DR, -DP, -DQ on psNAV-M1-3408-GS(+) hepatocyte was reduced 83.27 %, 88.93 %, 58.82 % respectively, the mRNA contents of CIITA, HLA-DR, -DP, -DQ and Ii decreased significantly. While T cell expressed less IL-2 mRNA in the case of psNAV-M1-3408-GS(+) hepatocyte.
CONCLUSION: The Ribonuclease P against CIITA-M1-3408-GS could effectively induce antigen-specific tolerance through cleaving CIITA. These results provided insight into the future application of M1-3408-GS as a new nucleic acid drug against allo-transplantation rejection and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12717860      PMCID: PMC4611376          DOI: 10.3748/wjg.v9.i5.1077

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

1.  Comparison of Abeta(b-/-), H2-DM(-), and CIITA(-/-) in second-set skin allograft rejection.

Authors:  Nathan J Felix; Suzan de Serres; Anthony A Meyer; Jenny P-Y Ting
Journal:  J Surg Res       Date:  2002-02       Impact factor: 2.192

2.  Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.

Authors:  Jack M Sullivan; Kathleen M Pietras; Bryant J Shin; John N Misasi
Journal:  Mol Vis       Date:  2002-04-08       Impact factor: 2.367

3.  [The mechanism of donor specific unresponsiveness in renal transplant recipients].

Authors:  T Okimoto; H Yahata; Y Fukuda; K Dohi
Journal:  Nihon Rinsho Meneki Gakkai Kaishi       Date:  1998-06

4.  In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment.

Authors:  C Cobaleda; I Sánchez-García
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

5.  Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications.

Authors:  R Esfand; D A. Tomalia
Journal:  Drug Discov Today       Date:  2001-04-01       Impact factor: 7.851

6.  Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors.

Authors:  M M Sadeghi; A Tiglio; K Sadigh; L O'Donnell; M Collinge; R Pardi; J R Bender
Journal:  Transplantation       Date:  2001-05-15       Impact factor: 4.939

7.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

8.  Modulation of IFN-gamma-induced immunogenicity by phosphatidylethanolamine-linked hyaluronic acid.

Authors:  Benito A Yard; Saul Yedgar; Martin Scheele; Diane van der Woude; Grietje Beck; Bärbel Heidrich; Miron Krimsky; Fokko J van der Woude; Stefan Post
Journal:  Transplantation       Date:  2002-03-27       Impact factor: 4.939

9.  Modulation of gene expression by the MHC class II transactivator.

Authors:  Uma M Nagarajan; Alyssa Bushey; Jeremy M Boss
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

10.  Design of a ribozyme targeting human telomerase reverse transcriptase and cloning of it's gene.

Authors:  Zhi-Ming Hao; Jin-Yan Luo; Jin Cheng; Quan-Yin Wang; Guang-Xiao Yang
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

View more
  1 in total

1.  Influence of liver nonparenchymal cell infusion combined with cyclosporin A on rejection of rat small bowel transplantation.

Authors:  Yan-Ling Yang; Ji-Peng Li; Ke-Feng Dou; Kai-Zong Li
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.